AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Solid Tumor

Treatments: Drug: AZD0530

Study type: Interventional

Funder types: Industry

Identifiers

NCT00704366

D8180C00021

Details and patient eligibility

About

This is a dose escalation study to assess the safety and tolerability of AZD0530 in patients with advanced solid malignancies.

Enrollment: 18 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed advanced carcinoma / solid tumour of known primary site, which is refractory to standard therapies or for which no standard therapy exists
• World Health Organisation (WHO) performance status 0 to 2
• Life expectancy of at least 12 weeks

Exclusion criteria

• Inadequate bone marrow reserve
• Inadequate liver function, renal function or low hemoglobin
• Unresolved toxicity from anti-cancer therapy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

18 participants in 1 patient group

1

Experimental group

Description:

AZD0530

Treatment:

Drug: AZD0530